A new global systematic review and meta-analysis has found that overusing short-acting beta-agonist (SABA) inhalers-commonly ...

A pilot study shows digital inhaler data can detect early signs of COPD exacerbations, offering promise for proactive disease ...

Between 14 days and 1 day out from an acute exacerbation of COPD, a digital inhaler measured significant drops in inhalation ...

Region residents are no strangers to tricky weather, well-accustomed to everything from winter snowstorms and deep freezes to ...

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

The GINA 2025 asthma update includes new guidance on T2 biomarkers, asthma in young children, and climate change, as well as ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

This updated asthma guideline establishes a consistent approach to improving asthma diagnosis and control in adults and ...

A first-in-class, pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide (an anti-inflammatory ...

Relvar Ellipta is a once-daily dual combination treatment comprising fluticasone furoate, an inhaled corticosteroid and vilanterol, a long-acting beta2-agonist, in a single inhaler, the Ellipta.

Read about the role of nurses in a pilot project by Asthma + Lung UK that has seen health professionals appointed as ...

Inhaled short acting beta-2 agonists, such as salbutamol or terbutaline, are commonly used as bronchodilators to relieve these symptoms. They can be used regularly or only when needed and are often ...